NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
11:45
The General Inspectorate of the Romanian Police announces a tender for the purchase of 736 vehicles, with an estimated value of 100,181,152 lei.
11:43
Donald Trump wants to restore the strategic reserve of the USA with Venezuelan oil.
11:32
ANPC has started inspections at fuel stations in the country, sanctioning operators who have increased prices after the legal hour.
11:29
The PSD leaders' meeting in Sinaia: What options PSD would propose to Nicușor Dan during consultations
11:19
Nicușor Dan, message for the Day of the Romanian Language: "For the first time we celebrate together in three countries, Romania, the Republic of Moldova, and Ukraine"
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
